LIPIDOR AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.25 SEK | +6.38% |
|
+6.38% | -50.40% |
| Sales 2021 | 15.6M 1.43M 119M | Sales 2022 | 292K 26.74K 2.23M | Capitalization | 21.33M 1.95M 163M |
|---|---|---|---|---|---|
| Net income 2021 | -21M -1.92M -160M | Net income 2022 | -41M -3.75M -313M | EV / Sales 2021 | 12.7 x |
| Net cash position 2021 | 51.31M 4.7M 392M | Net cash position 2022 | 8.93M 817K 68.17M | EV / Sales 2022 | 42.5 x |
| P/E ratio 2021 |
-11.1
x | P/E ratio 2022 |
-0.52
x | Employees | 8 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 65.26% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.38% | ||
| 1 week | +6.38% | ||
| Current month | -55.52% | ||
| 1 month | -46.12% | ||
| 3 months | -46.81% | ||
| 6 months | -70.24% | ||
| Current year | -50.40% |
1 week
0.21
0.32
1 month
0.180.60
Current year
0.181.35
1 year
0.182.30
3 years
0.1818.80
5 years
0.1824.35
10 years
0.1824.35
| Managers | Title | Age | Since |
|---|---|---|---|
Ola Holmlund
CEO | Chief Executive Officer | 55 | 01/18/01 |
Jan Holmbäck
FOU | Founder | 67 | 01/09/01 |
Charlotta Ekman
DFI | Director of Finance/CFO | 43 | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 01/19/01 |
Denis Angioletti
BRD | Director/Board Member | 56 | 01/20/01 |
Ola Flink
BRD | Director/Board Member | 80 | 01/17/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.25 | +6.38% | 25 143 |
| 26/24/26 | 0.235 | +2.17% | 71,781 |
| 25/24/25 | 0.23 | 0.00% | 77,552 |
| 24/24/24 | 0.23 | -2.54% | 42,298 |
| 23/24/23 | 0.236 | +0.43% | 35,206 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 08:48 pm IST
More quotes
Lipidor AB is a Sweden-based drug delivery company focusing on topical medication. The Company is focused to develop, patent and commercialize formulation concepts and technologies based on lipids. The Company develops product concepts based on AKVANO technology, which represents a dosage form that creates a lipid layer on the skin surface for effective delivery of drugs and skin care treatment. The Companyâs cooperation partners include Cerbios-Pharma, which specializes in the development and manufacturing of chemical and biological active pharmaceutical ingredients (APIs), and Aurena Laboratories AB, a manufacturer of bag-on-valve aerosol sprays for the pharmaceutical and medical device industry.
Sector
Pharmaceuticals
Calendar
22/05/2024
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.40% | 621K | |
| +26.09% | 661B | |
| +26.74% | 566B | |
| -6.53% | 352B | |
| +18.84% | 332B | |
| +3.82% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.14% | 145B |
- Stock Market
- Equities
- LIPI Stock
